Panel backs pain drug studies with new safety checks
Abstract
The wait may be over for drugmakers developing the first ever antibody-based painkillers. Despite safety concerns that led the US Food and Drug Administration (FDA) to temporarily halt nearly all trials involving these new agents—which target the nerve growth factor (NGF) protein—an advisory committee to the agency voted overwhelmingly last month to recommend allowing such studies to resume. “There was clearly a recognition that this is a new class of drugs, and it could...